Use of Ribavirin and Low Dose Ara-C to Treat Acute Myeloid Leukemia

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
The Leukemia and Lymphoma Society
Information provided by (Responsible Party):
Sarit Assouline, Jewish General Hospital
ClinicalTrials.gov Identifier:
NCT01056523
First received: January 25, 2010
Last updated: March 18, 2014
Last verified: March 2014

January 25, 2010
March 18, 2014
January 2010
September 2014   (final data collection date for primary outcome measure)
  • Recommended phase II dose of ribavirin when given in combination with low-dose ara-C [ Time Frame: 6-9 months ] [ Designated as safety issue: Yes ]
  • Maximum tolerated dose [ Time Frame: 6-9 months ] [ Designated as safety issue: Yes ]
  • Overall response rate (complete remission (CR), complete remission with incomplete blood count recovery (CRi), partial remission (PR) or blast response (BR)) [ Time Frame: 2-3 years ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01056523 on ClinicalTrials.gov Archive Site
  • Time to response [ Time Frame: 2-3 years ] [ Designated as safety issue: No ]
  • Duration of response [ Time Frame: 2-3 years ] [ Designated as safety issue: No ]
  • Time to relapse [ Time Frame: 2-3 years ] [ Designated as safety issue: No ]
  • One year and overall survival [ Time Frame: 1-4 years ] [ Designated as safety issue: No ]
  • Hematological Improvement [ Time Frame: 6 months - 2 years ] [ Designated as safety issue: No ]
  • Safety and tolerability of ribavirin and low dose ara-C [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
  • Correlation between expression and activity of eIF4E and response [ Time Frame: 6months - 2 years ] [ Designated as safety issue: No ]
  • Effect of ribavirin and low dose ara-C on the activity of eIF4E related pathways. [ Time Frame: 6 months- 2 years ] [ Designated as safety issue: No ]
  • Time to response [ Time Frame: 2-3 years ] [ Designated as safety issue: No ]
  • Duration of response [ Time Frame: 2-3 years ] [ Designated as safety issue: No ]
  • Time to relapse [ Time Frame: 2-3 years ] [ Designated as safety issue: No ]
  • One year and overall survival [ Time Frame: 1-4 years ] [ Designated as safety issue: No ]
  • Hematological Improvement [ Time Frame: 6 months - 2 years ] [ Designated as safety issue: No ]
  • Safety and tolerability of ribavirin and low dose ara-C [ Time Frame: Phase I/II ] [ Designated as safety issue: Yes ]
  • Correlation between expression and activity of eIF4E and response [ Time Frame: 6months - 2 years ] [ Designated as safety issue: No ]
  • Effect of ribavirin and low dose ara-C on the activity of eIF4E related pathways. [ Time Frame: 6 months- 2 years ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Use of Ribavirin and Low Dose Ara-C to Treat Acute Myeloid Leukemia
A Phase I/II Study of Ribavirin and Low-dose Cytarabine Arabinoside (Ara-C) in Acute Myeloid Leukemia (AML) M4 and M5 Subtypes, and AML With High eIF4E Expression

The purpose of the study is to determine the maximum tolerated dose of ribavirin, when given in combination with low-dose ara-C and to determine if it is safe and well-tolerated in patients with acute myeloid leukemia.

Primary Objectives

In the Phase I portion of this study, we will determine the maximum tolerated dose and recommended phase II dose (RP2D) of ribavirin and low-dose ara-C. The primary objective of the Phase II portion of the study is to determine the overall response rate, including the complete remission (CR), complete remission with incomplete blood count recovery (CRi), partial remission (PR) or blast response (BR), to therapy with ribavirin and low dose ara-C at the RP2D.

STUDY DESIGN AND DURATION

This is a multicentre, open-label, single arm Phase I/II study of oral ribavirin and low-dose ara-C for patients with AML M4/M5 or AML with high expression of eIF4E, who have relapsed or refractory disease, or who are not suitable candidates for induction chemotherapy. This study will determine the recommended phase II dose and will evaluate efficacy. Correlative studies will be included to assess relevant molecular targets.

Interventional
Phase 1
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Acute Myeloid Leukemia
  • Drug: Ribavirin
    Dose level 1 = 1000 mg po BID/ Dose level 2 = 1400 mg po BID/ Dose level 3 = 1800 mg po BID
  • Drug: Cytarabine arabinoside
    Previous cohorts at 20 mg bid days 1 to 10 of every 28 day cycle. Dosage modified to 10 mg bid days 1 to 10 of every 28 day cycle for more recent cohorts.
    Other Name: Ara-C
Experimental: Ribavirin-Cytarabine
Interventions:
  • Drug: Ribavirin
  • Drug: Cytarabine arabinoside

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
30
Not Provided
September 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • The following patients with acute myeloid leukemia (AML) are eligible:

    • De novo AML M4 or M5 FAB subtype or high eIF4E.
    • Secondary AML after a myelodysplastic syndrome (MDS) or a myeloproliferative disorder (not chronic myelogenous leukemia), if M4 or M5 FAB subtype or high eIF4E.
    • Therapy-related AML if M4 or M5 FAB subtype or high eIF4E.
    • CML blast crisis if they have failed imatinib and at least one other tyrosine kinase inhibitor.
  • All patients must have failed primary therapy (defined as two induction chemotherapies), have relapsed, or are not suitable candidates for intensive induction chemotherapy.
  • Patients who have a dry aspirate or extramedullary disease only are eligible for this study if they have a pre-treatment marrow or tissue biopsy demonstrating AML M4 or M5 subtype or high eIF4E expression.
  • ECOG performance status 0, 1, 2 or 3.
  • Life expectancy > 4 weeks.
  • Age is > 18 years.
  • Female patients of childbearing potential must have a negative serum (beta-HCG) pregnancy test within 14 days of starting protocol and must not be breastfeeding. Men and women of childbearing potential must agree to use an effective means of contraception throughout the study and for at least 30 days after completion of protocol.
  • Adequate renal and hepatic function: serum creatinine < 1.5 x ULN; AST or ALT < 2.5 x ULN (or < 5 x ULN if liver involvement with leukemia); serum bilirubin < 1.5 x ULN.
  • Provide written consent after the investigational nature, study design, risks and benefits of the study have been explained.
  • Accessible for treatment and follow up.

Exclusion Criteria:

  • Uncontrolled central nervous system involvement by AML.
  • Active cardiovascular disease as defined by New York Heart Association (NYHA) class III-IV categorization.
  • Intercurrent illness or medical condition precluding safe administration of the planned protocol treatment or required follow-up.
  • Received any previous therapy for AML within 28 days prior to the study entry. Hydrea is permitted for the treatment of leukocytosis but must be stopped within 7 days of starting low dose ara-C and ribavirin.
  • Female patients who are pregnant or breastfeeding.
  • Concurrent treatment with other anti-cancer therapy.
  • Known infection with HIV.
  • History of other malignancy. Subjects who have been disease-free for 2 year or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible.
  • FAB AML M1, 2, 6, 7 will be excluded if they do not have high eIF4E expression. AML M3 is always excluded.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT01056523
Ribavirin-002
No
Sarit Assouline, Jewish General Hospital
Jewish General Hospital
The Leukemia and Lymphoma Society
Principal Investigator: Sarit Assouline, MD Jewish General Hospital, McGill University
Study Director: Katherine Borden, PhD Université de Montréal
Jewish General Hospital
March 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP